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Abstract
Mutations in PINK1 and parkin cause autosomal recessive parkinsonism, a neurodegenerative
disorder characterized by the loss of dopaminergic neurons. To highlight potential therapeutic
pathways we have identified factors that genetically interact with parkin/PINK1. Here we report
that overexpression of the translation inhibitor 4E-BP can suppress all pathologic phenotypes
including degeneration of dopaminergic neurons in Drosophila. 4E-BP is activated in vivo by the
TOR inhibitor rapamycin, which we find can potently suppress pathology in PINK1/parkin
mutants. Rapamycin also ameliorates mitochondrial defects in cells from parkin-mutant patients.
Recently, 4E-BP was shown to be inhibited by the most common cause of parkinsonism, dominant
mutations in LRRK2. Here we further show that loss of the Drosophila LRRK2 homolog activates
4E-BP and is also able to suppress PINK1/parkin pathology. Thus, in conjunction with recent
findings our results suggest that pharmacologic stimulation of 4E-BP activity may represent a
viable therapeutic approach for multiple forms of parkinsonism.
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Parkinson disease (PD) is the most common neurodegenerative movement disorder,
affecting ~1% of the elderly population. There are currently no cure and no effective
disease-modifying therapies. The pathology of PD is principally characterized by the loss of
dopaminergic neurons in the substantia nigra which causes progressive loss of motor
functions and other symptoms. The precise pathologic mechanisms remain unclear,
however, the identification of several genes associated with rare, heritable forms of PD have
highlighted putative pathogenic causes such as mitochondrial dysfunction and aberrant
protein degradation1, 2. In addition, oxidative stress is a prominent and common feature in
all forms of PD and likely represents a convergent toxic event leading to neuronal cell death.
Disruption of two genes, parkin, which encodes an E3 ubiquitin ligase, and PINK1,
encoding a mitochondrially targeted kinase, result in autosomal recessive parkinsonism2.
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Recent analyses have revealed that PINK1 and Parkin act in a common pathway that
maintains mitochondrial integrity3-6. Genetic studies of the Drosophila PINK1 and parkin
mutants, which exhibit dopaminergic neurodegeneration, locomotor deficits and
mitochondrial dysfunction, have been instrumental in understanding the pathogenesis and
highlighting potential protective pathways7. Additional components of the PINK1/Parkin
pathway8, 9 and its function in affecting mitochondrial dynamics6, 10-12 are being
elucidated, however, it is currently unclear how these pathologic effects may be
circumvented to prevent neurodegeneration. To address this we previously conducted a
genetic screen for modifiers of Drosophila parkin mutants to identify factors that enhance or
suppress parkin pathology. This approach has the potential to identify factors acting directly
on the PINK1/Parkin pathway or indirectly, highlighting parallel pathways that mediate cell-
protective mechanisms. In this screen we identified the Drosophila gene Thor, which
encodes the sole ortholog of mammalian 4E-BP113. 4E-BP1 is an inhibitor of translation
that has previously been implicated in mediating the survival response to various
physiological stresses14-16.
The ability of a cell to elicit a rapid response to intrinsic or extrinsic stress is essential for
survival. Regulated control of translation is an elaborate mechanism that allows immediate
changes in gene expression from existing mRNAs. Initiation of translation is the rate-
limiting step, and thus subject to precise regulation. Translation initiation is governed by the
eukaryotic initiation factor 4E (eIF4E), which mediates the binding of the eIF4F complex to
the mRNA 5ᓉ cap structure16, 17. The availability of eIF4E is regulated by eIF4E-binding
proteins (4E-BPs), which bind and sequester eIF4E, preventing eIF4F complex formation
and translation. In turn, the activity of 4E-BPs is tightly regulated by phosphorylation.
Hypo-phosphorylated 4E-BP1 binds eIF4E with high affinity, however, upon hyper-
phosphorylation 4E-BP1 dissociates from eIF4E allowing 5ᓉ cap-dependent translation to
occur. Central to the regulation of 4E-BP phosphorylation is the conserved TOR signaling
pathway. TOR is activated in response to numerous stimuli including activation of the PI3K/
Akt1 pathway, whereupon it phosphorylates 4E-BP and other factors promoting translation.
Thus, TOR signaling coordinates cell growth and metabolism in response to physiological
changes18, 19.
Inhibition of cap-dependent translation by 4E-BP is essential for survival under stress
conditions. 4E-BP has been shown to be important for survival under a wide variety of
stresses including starvation, oxidative stress, unfolded protein stress and immune
challenge20-24. Many cellular stressors result in the rapid cessation of cap-dependent
translation, which is accompanied by the concomitant promotion of cap-independent
translation of essential pro-survival factors14, 25. Switching the translational profile from
cap-dependent to cap-independent provides the cell with ability to rapidly respond to
environmental changes and transient stresses.
Here we show in Drosophila that loss of 4E-BP function dramatically reduces parkin and
PINK1 mutant viability. In contrast, overexpression of 4E-BP is sufficient to suppress all
pathologic phenotypes in these mutants, including neurodegeneration. We also show that
activation of 4E-BP by pharmacologic inhibition of its negative regulator TOR with
rapamycin is able to elicit a similar protective effect in vivo. Importantly, rapamycin
treatment is also able to ameliorate mitochondrial defects in parkin-mutant PD patient cell
lines. Furthermore, we provide the first evidence that the Drosophila homolog of LRRK2
genetically interacts with PINK1/parkin mutants, consistent with a recent report showing
LRRK2 regulates the activity of 4E-BP26. Thus, our results suggest that modulating 4E-BP
activity represents a viable therapeutic target to modify the pathologic process and may be
applicable to multiple forms of parkinsonism.
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RESULTS
4E-BP genetically interacts with the Parkin/PINK1 pathway
In a screen for parkin modifiers we previously recovered a P-element neighboring the
Drosophila gene Thor, which encodes the sole ortholog of mammalian 4E-BP113. [Here we
refer to the endogenous gene as Thor, as per established FlyBase nomenclature, and
transgenes or the protein as 4E-BP.] To confirm and extend the analysis of this genetic
interaction we obtained an independent, previously characterized null allele Thor2 to cross
with null mutations in parkin (park25) and PINK1 (PINK1B9).
In contrast to parkin and PINK1 mutants, homozygous Thor2 mutants are fully viable and
fertile, and show no overt phenotypes under normal conditions20. Surprisingly, we found
Thor2:park25 double mutants were essentially lethal (Supplementary Fig. S1a). Rare
escapers were occasionally recovered but died shortly after eclosing as adults. This synthetic
lethality could be rescued by targeted expression of a 4E-BP wild type transgene.
(Supplementary Fig. S1b). Similarly, we found Thor2:PINK1B9 double mutants showed a
significant reduction in viability (Fig. S1c), although the degree of interaction was not as
severe. Heterozygous combinations of Thor2 and park25 or PINK1
-
B9
 mutations had no
significant effect on viability.
4E-BP overexpression suppresses parkin/PINK1 phenotypes
Since loss of 4E-BP is detrimental to parkin and PINK1 mutants, we reasoned that increased
4E-BP expression may confer a protective effect. PINK1 and parkin mutants exhibit
locomotor deficits in flight and climbing ability, widespread muscle degeneration and
mitochondrial defects. Overexpression of 4E-BP, using the muscle specific 24B-GAL4
driver, significantly suppressed climbing and flight defects in both parkin and PINK1
mutants (Fig. 1a-d). Muscle degeneration and mitochondrial disruption seen in parkin/
PINK1 mutants was also abrogated by 4E-BP overexpression (Fig. 1e-p).
park25 and PINK1B9 mutants exhibit age-related degeneration of a subset of dopaminergic
neurons4, 27. The tyrosine hydroxylase-GAL4 line (THG4) was used to drive expression of
4E-BP in dopaminergic neurons of parkin and PINK1 mutants and the number of
dopaminergic neurons surviving in the PPL1 cluster of aged animals was analyzed.
Strikingly, we found that overexpression of 4E-BP in PINK1 and parkin mutants was
capable of significantly suppressing dopaminergic neuron loss (Fig. 2a) in parkin and
PINK1 mutants. Interestingly, consistent with a previous study26 Thor2 mutants also display
loss of dopaminergic neurons (Fig. 2b). Together these findings indicate that 4E-BP is
required to prevent neurodegeneration and increasing 4E-BP levels is capable of mediating a
protective mechanism sufficient to prevent the pathologic consequence of loss of Parkin or
PINK1.
4E-BP pathway is activated in parkin/PINK1 mutants
To gain insight into the status of 4E-BP activity in parkin/PINK1 mutants, we examined the
transcriptional, translational and post-translational state of 4E-BP. First, we quantified the
relative levels of Thor transcript and found that the levels were not significantly different in
mutants compared to wild type (Supplementary Fig. S2a). 4E-BP activity is regulated by
altered phosphorylation state so we examined the relative levels of phosphorylated and non-
phosphorylated 4E-BP. Western blot analysis revealed that there was a significant reduction
in the level of hyper-phosphorylated 4E-BP in parkin and PINK1 mutants, and a
concomitant increase in the proportion of active, non-phosphorylated 4E-BP (Fig. 3a,b).
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Under normal conditions 4E-BP function is actively repressed by the Akt1/TOR signaling
pathway, thus, the previous result suggests that this pathway itself may be down-regulated in
response to loss of parkin/PINK1 function. To assess the broader effects of parkin/PINK1
mutations on the pathway that regulates 4E-BP we examined the activity status of Akt1, an
upstream regulator of 4E-BP which is itself activated by phosphorylation. The relative
amount of active, phosphorylated Akt1 is markedly reduced in parkin and PINK1 mutants
(Fig. 3c,d), indicating a down-regulation of this pathway.
Akt1 signaling inactivates the transcription factor FOXO which regulates the expression of
Thor28, 29. FOXO is also known to regulate the expression of a large number of stress
response factors and detoxification enzymes30, 31, and has been shown to influence lifespan
and stress resistance across taxa including Drosophila32, 33. Thus, we sought to test
whether overexpression of FOXO modulated parkin and PINK1 phenotypes. While
widespread overexpression of FOXO is lethal in a wild-type background, we surprisingly
recovered viable parkin mutants overexpressing FOXO, however, overexpression in a
PINK1 mutant background was lethal. Interestingly, we found that FOXO overexpression
significantly rescued the flight and climbing defects (Fig. 1a,b), restored muscle integrity
(Fig. 1k,l), and prevented dopaminergic neuron loss in parkin mutants (Fig. 2a) to the same
extent as 4E-BP overexpression.
These results indicate that in parkin/PINK1 mutants the Akt1/TOR signaling pathway that
regulates 4E-BP activity and global protein translation is down-regulated typical of a stress
response to promote protective mechanisms. Our genetic studies indicate that this
endogenous mechanism can be ectopically further upregulated, therefore, we next sought to
achieve this by pharmacologic inhibition of TOR signaling.
Rapamycin suppresses parkin/PINK1 pathology
4E-BP is negatively regulated via phosphorylation by TOR which can be inhibited by
exposure to rapamycin34. Therefore, we reasoned that administering rapamycin to parkin/
PINK1 mutants could promote 4E-BP hypo-phosphorylation and confer a protective effect.
Mutant and control flies were raised on normal food supplemented with rapamycin or
vehicle alone. Consistent with previous reports35, 36, we found rapamycin treatment led to
4E-BP hypo-phosphorylation in vivo (Supplementary Fig. S2b,c).
Treatment with rapamycin significantly reduced the appearance of thoracic indentations, a
surrogate marker for flight muscle degeneration, in both parkin and PINK1 mutants (Fig.
4a). In addition, mutant flies fed rapamycin showed suppression of the climbing deficits,
muscle degeneration and mitochondrial defects in the mutant flies (Fig. 4b,d-i). Remarkably,
we also found that in parkin and PINK1 mutant flies raised and aged on rapamycin
supplemented food dopaminergic neurodegeneration was completely suppressed (Fig. 4c).
Treatment of Drosophila cells treated with dsRNA against parkin, which causes a dramatic
reduction in parkin transcript and protein levels (Supplementary Fig. S3a,b), leads to a
significant elongation of the mitochondrial reticulum (Fig. 5a), similar to the recently
reported mitochondrial elongation in fibroblasts from PD patients with parkin mutations12.
Co-treatment with rapamycin effectively suppressed the mitochondrial morphology defects
in parkin-deficient Drosophila cells (Fig. 5a). We wanted to extend these findings to
determine whether rapamycin treatment is relevant to human pathology. Strikingly,
rapamycin treatment of parkin-deficient fibroblasts was also able to suppress the
mitochondrial elongation and partially rescue the loss of membrane potential (Fig. 5b,c).
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The effects of rapamycin are mediated by 4E-BP
Inhibition of TOR by rapamycin exerts effects in addition to those on 4E-BP, for example
promoting autophagy. Autophagy has received much attention as a putative protective
mechanism in neurodegenerative diseases, particularly in the clearance of misfolded or
undegraded proteins. Thus, we wished to determine whether the beneficial effects of
rapamycin are operating through 4E-BP-dependent or 4E-BP-independent mechanisms, or a
combination.
To address this directly, we took a genetic approach to test whether the rapamycin protection
required 4E-BP. parkin and PINK1 mutants were placed in combination with Thor2 null
mutations and administered rapamycin or vehicle as before. Rapamycin treatment again
improved viability and reduced the presence of thoracic indentations in parkin and PINK1
mutants (Fig. 6a,b), however, in a homozygous Thor2 mutant background, suppression of
parkin/PINK1 phenotypes was completely abolished (Fig. 6a,b). In contrast, attenuating the
induction of autophagy by RNAi mediated knock-down of Atg5 (Supplementary Fig. S3c)
had no effect on the rapamycin-induced suppression of parkin/PINK1 phenotypes (Fig.
6c,d). These results indicate that the beneficial effects of rapamycin require the activity of
4E-BP and not autophagy. Consistent with this we also found that rapamycin did not prevent
degeneration of dopaminergic neurons in Thor2 mutants (Fig. 2b).
4E-BP activity upregulates the detoxifying enzyme GstS1
Active 4E-BP induces the rapid cessation of cap-dependent translation to promote the
upregulation of stress response factors such as antioxidants and chaperones. The precise
changes to the proteomic signature induced upon 4E-BP activation are currently unknown
but are likely to be numerous. We previously showed that transgenic overexpression of the
antioxidant and detoxifying enzyme GstS1 was sufficient to suppress parkin phenotypes27,
therefore, it seemed possible that upregulation of GstS1 may constitute part of the 4E-BP
mediated stress response.
Assessing the protein levels of GstS1 we found they were increased upon either transgenic
overexpression of 4E-BP or the administration of rapamycin (Fig. 7). Together with our
previous findings, this supports a role for the upregulation of stress response factors by
activation of 4E-BP. Further work to elucidate the exact translational changes induced by
4E-BP activity will provide important insight into the molecular mechanisms that promote
neuro-protection.
Genetic interaction with Drosophila LRRK2 homolog
Dominant pathogenic mutations in LRRK2 are known to cause aberrant increase in its
kinase activity37, 38. Recently, it was shown that 4E-BP is a substrate of human LRRK2
and the Drosophila ortholog (LRRK) and that pathogenic mutations cause hyper-
phosphorylation of 4E-BP in vivo, leading to reduced oxidative stress resistance and
dopaminergic neurodegeneration26. We therefore hypothesized that loss of LRRK2 would
lead to hypo-phosphorylated 4E-BP, which should promote a protective response.
In agreement with Imai et al.26, we find that homozygous LRRKe03680 loss-of-function
mutations cause a decrease in levels of phosphorylated 4E-BP compared to wild type (Fig.
8a,b), although this does not detectably decrease further in parkin/PINK1 mutant adults.
LRRK mutants exhibit normal flight and mildly reduced climbing ability (Fig. 8d,e),
however, we found that combining homozygous LRRKe03680 with parkin/PINK1 mutations
significantly rescued the dopaminergic neuron loss, flight and climbing deficits of parkin
and PINK1 mutants (Fig. 8c-e). These results are consistent with normal LRRK function, in
part, negatively regulating survival programs necessary for dopaminergic neuron survival.
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Discussion
We have used Drosophila as a model system to uncover genetic suppressors in order to
understand the pathogenic mechanisms and to highlight putative therapeutic pathways for
PD. We previously identified Thor, the sole Drosophila homolog of mammalian 4E-BP1, as
a genetic modifier of parkin. In the present study, we have further characterized the genetic
interaction of Thor with parkin and PINK1. While loss-of-function mutations in Thor
dramatically decrease parkin and PINK1 mutant viability, overexpression of 4E-BP is able
to suppress PINK1 and parkin mutant phenotypes, including degeneration of dopaminergic
neurons. These results suggest that 4E-BP acts to mediate or promote a survival response
implemented upon loss of parkin or PINK1.
4E-BP1 is an inhibitor of 5ᓉ cap-dependent protein translation, which is known to play an
important role in cellular response to changes in environmental conditions such as altered
nutrient levels and various physiological stresses14, 25. It has been demonstrated that
Drosophila 4E-BP is important for survival under a wide variety of stresses including
starvation, oxidative stress, unfolded protein stress and immune challenge20-23. Such a
response pathway represents a likely target for possible manipulation by therapeutics. Our
genetic evidence supports this idea, hence, we sought to validate whether this represented a
viable therapeutic target.
4E-BP activity is regulated post-translationally by the TOR signaling pathway. Activated
TOR hyper-phosphorylates 4E-BP inhibiting it leading to promotion of 5ᓉ cap-dependent
translation18, 39. Rapamycin is a small molecule inhibitor of TOR signaling and has been
shown to lead to 4E-BP hypo-phosphorylation in vitro and in vivo35, 36. Our genetic
evidence suggested that administration of rapamycin to parkin/PINK1 mutants should
relieve 4E-BP inhibition and confer a protective effect. Exposing mutant animals to
rapamycin during development caused an increase in hypo-phosphorylated 4E-BP and,
remarkably, was sufficient to suppress all pathologic phenotypes, including muscle
degeneration, mitochondrial defects and locomotor ability. Continued administration of
rapamycin during aging also completely suppressed progressive degeneration of
dopaminergic neurons..
To validate this pathway as a viable target for therapy we extended our studies to human
tissue. There is growing evidence that mitochondrial dysfunction is a key pathologic event
across the spectrum of parkinsonism. We and others have reported mitochondrial defects in
a number of cell lines derived from patients with parkin mutations12, 40. Here we show that
rapamycin is also capable of ameliorating mitochondrial bioenergetic and morphological
defects in parkin-deficient PD patient cell lines. Thus, our results provide strong support for
the proposition that modulating 4E-BP mediated translation by pharmaceuticals such as
rapamycin can be efficacious in vivo and is relevant to human pathophysiology.
TOR signaling regulates a number of downstream effectors other than 4E-BP, for example,
up-regulation of S6 kinase promoting protein synthesis and cell proliferation, and down-
regulation of autophagy likely through inhibition of ATG119. The coordinated regulation of
these pathways serves to optimize cellular activity in response to vital changes such as
nutrient availability and environmental stresses. Stimulation of autophagy under nutrient-
deprived conditions is a survival mechanism that recycles essential metabolic components,
but this mechanism also promotes the degradation of aggregated or misfolded proteins.
Thus, the potential therapeutic effects of rapamycin have been widely promoted as a strategy
to combat a number of neurodegenerative diseases including PD primarily for its perceived
role in promoting autophagic clearance of aggregated proteins. However, recent studies have
provided compelling evidence that the pro-survival effects of rapamycin can be mediated in
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the absence of autophagy by reducing protein translation41, 42. We have demonstrated here
that genetic ablation of 4E-BP is sufficient to completely abrogate any beneficial effects of
rapamycin in vivo while inhibiting Atg543, a key mediator of autophagy44, does not
diminish the efficacy of rapamycin-mediated protection. Together, these results indicate that
in this instance the major protective effects of rapamycin treatment are mediated through
regulated protein translation, with little or no contribution from autophagy.
A switch from cap-dependent to cap-independent translation is likely to effect widespread
changes in the proteome, particularly the induction of pro-survival factors including
chaperones, anti-oxidants and detoxifying enzymes. In support of this, we have shown that
transgenic or rapamycin-induced 4E-BP activation leads to increased protein levels of
GstS1, a major detoxification enzyme in Drosophila45. Interestingly, we previously showed
that transgenic overexpression of Drosophila GstS1 is able to suppress dopaminergic neuron
loss in parkin mutants27. Elucidating the global changes in response to 4E-BP activation
will be crucial to understanding the exact molecular mechanisms of neuro-protection but
currently remains unresolved.
The potential importance of 4E-BP modulation as a therapeutic target is underscored by
recent findings that report the most common genetic cause of PD, dominant mutations in
LRRK2, inhibit 4E-BP function through direct phosphorylation26. Expression of these
mutations causes disruption of dopaminergic neurons in Drosophila26 and mouse46,
however, in striking similarity to our results, overexpression of 4E-BP can circumvent the
pathogenic effects of mutant LRRK2 and prevent neurodegeneration26 in Drosophila. Here
we show that loss of Drosophila LRRK leads to activation of 4E-BP and can suppress
pathology in PINK1 and parkin mutants. These data further support a link between LRRK2
and 4E-BP activity and a common cause of PD. Thus, our results indicate that promoting
4E-BP activity may be beneficial in preventing neurodegeneration in multiple forms of
parkinsonism. Since 4E-BP activity can be manipulated by small molecule inhibitors such as
rapamycin, this pathway represents a viable therapeutic target. It will be particularly
interesting to determine whether rapamycin is efficacious in ameliorating pathologic
phenotypes in the recently reported LRRK2 transgenic mouse model46, but further studies
will be necessary to determine whether pharmacologic modulation of 4E-BP function is
therapeutically relevant in all forms of parkinsonism including sporadic PD.
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Appendix
Methods
Fly stocks and procedures
Drosophila were raised under standard conditions at 25°C on agar, cornmeal, yeast food.
park25 mutants have been described before47. pink1B9 mutants4 were provided by J. Chung
(KAIST) and the tyrosine hydroxylase-GAL4 (THG4) driver was a gift from S. Birman
(Institute of Marseille, France). UAS-FOXO48 was provided by L. Partridge (UCL, London)
and UAS-4E-BP49 was obtained from N. Sonenberg (McGill University). UAS-Atg5-RNAi
was provided by T. Neufeld43. 24B-GAL4, da-GAL4, PBac{RB}LRRKe03680 and Thor2
strains were obtained from the Bloomington Drosophila Stock Center (Bloomington, IN).
A high proportion of X-chromosome non-disjunction occurs in PINK1 mutant stocks, so
crosses to combine PINK1 mutants with GAL4/UAS transgenes used paternal males with y-
or FM7-GFP backgrounds to allow correct identification of PINK1 mutant progeny. Flight
and climbing assays were performed as previously described47. Rapamycin (Sigma-
Aldrich) was added to standard fly food at 0.5 ͮm for larval feeding and at 200 ͮm for adult
feeding.
Histology
Tissue sectioning and TEM—Thoraces were prepared from 5-day old adult flies and
treated as previously described (Greene et al. 2003). Semi-thin sections were then taken and
stained with Toluidine blue, while ultra-thin sections were examined using a TEM (FEI
tecnai G2 biotwin 120KV).
Brains were dissected from 30-day old flies and treated for anti-tyrosine hydroxylase
(Immunostar Inc.) staining as described previously27. Brains were manipulated, imaged by
confocal microscopy and tyrosine hydroxylase-positive neurons counted under blinded
conditions.
Western blotting
Proteins were resolved by either 12% or 15% SDS-PAGE and transferred onto PVDF
membrane. Membranes were blocked by PBS-T BSA (5%) for 1hr. Antibodies were
incubated in blocking solution at a 1:1000 dilution (with the exception of anti-Actin -
1:10000, for 1hr) overnight at 4°C, washed repeatedly in PBS-T. Incubation with secondary
antibody was carried out with either anti-mouse or anti-rabbit, HRP-conjugated antibody.
Detection was carried out by ECL-Plus detection kit (Amersham) and comparative protein
levels were quantified by densitometry using Image-J.
Antibodies—anti-phosho 4E-BP(Thr/Ser 37/46), anti-non-phospho 4E-BP, anti-phosho
Akt1 and anti-Akt1 were obtained from Cell Signaling Technologies and anti-Actin from
Sigma-Aldrich. Anti-GstS145 was a kind gift from H. Benes (University of Arkansas for
Medical Sciences). Anti-Parkin has been previously described13.
Quantitative PCR (qPCR)
Total RNA from live cells/flies was prepared from three to four replicates of each genotype/
treatment, using TRIzol reagent (Sigma). The purity of RNA was then determined
spectrophotometrically (NanoDrop). Once treated with DNase, total RNA was reverse-
transcribed using RETROscript (Ambion) according to the manufacturers protocol. qPCR
was performed using SYBR Green (Sigma) on a MyiQ real time PCR detection system
(Bio-Rad). Each PCR included three or four biological replicates, which were repeated three
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times (technical replicates). For each transcript, levels were normalized to a GAPDH control
by the 2-͇͇CT method. The following primer pairs were used:
Gapdh-F; GCGAACTGAAACTGAACGAG
Gapdh-R; CCAAATCCGTTAATTCCGAT
RpL32-F; GACGCTTCAAGGGACAGTATCTG
RpL32-R; AAACGCGGTTCTGCATGAG
parkin-F; AATGAAACTCTGTTGGACTTGC
parkin-R; CGGACTCTTTCTTCATCGCT
Thor-F; TCCTGGAGGCACCAAACTTA
Thor-R; AGCGACTTGGTCTGCTTGAT
Atg5-F; GACATCCAACCGCTCTGCGCA
Atg5-R; GGTGTACGTGAAGTCATCGTCTG
Cell culture
Drosophila S2R+ cells were grown in Schneider’s medium (Gibco) containing 10% heat-
inactivated fetal bovine serum (Sigma). dsRNA was generated, as per manufacturers
protocols, using the MEGAscript T7 in vitro transcription kit (Ambion). 15ͮg of dsRNA
was added in serum free media to S2R+ cells (1.2×106/ml) for 1h, after which cells were
incubated (3d) at 25°C. Control cells were treated with dsRNA against DsRed. The
following primer pairs were used to generate dsRNAs:
parkin-F, TAATACGACTCACTATAGGGCTGTTGCAATTTGGAGGGA
parkin-R, TAATACGACTCACTATAGGGCTTGGCACGGACTCTTTCT
DsRed-F; TAATACGACTCACTATAGGGAAGGTGTACGTGAAGCACCC
DsRed-R; TAATACGACTCACTATAGGGTAGTCCTCGTTGTGGGAGGT
Rapamycin (50nM) treatment was carried out on individual imaging dishes for 48hr prior to
imaging. Rapamycin containing medium was first removed and replaced with medium
containing 200ͮm Rhodamine-123 (40s). Cells were then repeatedly washed and finally the
original, Rapamycin containing, medium was replaced.
Mitochondrial Morphology Assessment
Fibroblasts were stained with the fluorescent dye rhodamine 123, plated as previously
described12. Mitochondria were then imaged using a Delta-vision RT microscope
(Drosophila cells) or a Zeiss LSM 510 confocal microscope (Fibroblasts). n ≥ 45 cells per
condition. Raw images were binarized and mitochondrial morphological characteristics
(aspect ratio and number per cell) were quantified as described previously50.
Measurement of mitochondrial membrane potential
Fibroblasts were cultured from 2 patients with parkin mutations and 3 normal controls.
Fibroblasts were plated at 40% confluency in 96 well plates; 24 hours later cells were
changed into galactose culture medium as described previously12. The mitochondrial
membrane potential was then measured using the fluorescent dye Tetramethylrhodamine
methyl ester (TMRM) after a further 24h as described previously12. In order to remove the
plasma membrane contribution to the TMRM fluorescence, each assay was performed in
parallel as earlier plus 10ͮM carbonyl cyanide 3-chlorophenylhydrazone (CCCP), which
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collapses the mitochondrial membrane potential. All data is expressed as the total TMRM
fluorescence minus the CCCP treated TMRM fluorescence. Cell number was measured
using the ethidium homodimer fluorescent dye in a parallel plate after freeze thawing.
Statistical Analyses
Viability and indentation counts—Statistical significance was carried out on individual
genotypes using Mann-Whitney non-parametric analysis as data failed to achieve normality.
Flight and climbing—n ≥ 30 per genotype, typically ~100. Statistical significance was
calculated by Kruskal-Wallis non-parametric analysis and Dunn’s pair-wise comparison.
Dopaminergic neuron counts—n ≥10 per genotype. Data was analyzed by Student t-
test, with Bonferroni correction.
Western blot and qPCR—Analysis were carried out on three or more biological
replicates and analysis was carried using two-tailed Student t-tests.
Mitochondrial analysis—As data failed to achieve normality, analysis of Drosophila
mitochondrial morphology was carried out using Kruskal-Wallis non-parametric analysis
and Dunn’s pair-wise comparisons. To account for multiple patient cell lines, analysis of
fibroblast mitochondrial morphology/membrane potential was carried out using two-way
ANOVA.
All statistical significance was calculated at p = 0.05, using GraphPad Prism 5.
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Figure 1. 4E-BP overexpression suppresses parkin/PINK1 locomotor deficits and muscle
degeneration
Overexpression of 4E-BP suppresses climbing and flight defects of (a, b) parkin and (c, d)
PINK1 mutants. Overexpression of FOXO also rescued locomotor deficits in parkin mutants
(a, b). (e-p) Toluidine blue stained sections of adult thorax and TEM images of muscle show
4E-BP or FOXO overexpression suppresses muscle degeneration and mitochondrial defects.
Abnormal mitochondrial morphology in mutants (black arrowheads) is restored (white
arrowheads). Scale bars show 1ͮm. Charts show mean and SEM. Significance was
determined by one-way ANOVA with Bonferroni correction (*** P<0.001).
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Figure 2. Overexpression of 4E-BP can suppress degeneration of dopaminergic neurons in
parkin/PINK1 mutants
Quantification of anti-tyrosine hydroxylase positive stained dopaminergic neurons in the
PPL1 cluster. (a) Effect of 4E-BP or FOXO overexpression in parkin or PINK1 mutants.
Control genotype: park25/+; THG4/+. (b) Thor2 mutants show loss of dopaminergic neurons
after 30 days compared to a revertant control. Charts show mean and SEM, n ≥ 10.
Significance was determined by one-way ANOVA with Bonferroni correction (***
P<0.001, * P<0.05).
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Figure 3. Post-translational state of 4E-BP activity in parkin/PINK1 mutants
(a) Western blot analysis of phosphorylated and non-phosphorylated 4E-BP levels in adult
tissue from control, parkin, and PINK1 mutant flies. Thor2 mutant flies were used as a
negative control. (b) Relative levels of phosphorylated and non-phosphorylated 4E-BP after
normalization for total levels of 4E-BP. (c) Western blots for phosphorylated and non-
phosphorylated Akt1 in control, parkin and PINK1 mutant adult tissue. (d) Quantified
proportion of phospho-Akt1 relative to total Akt1. Charts show mean and SEM of at least
three independent experiments. Significance was determined by Student’s t-test with
Bonferroni correction (***P<0.001, *P<0.05).
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Figure 4. Pharmacological suppression of parkin/PINK1 mutant phenotypes by rapamycin
(a) Thoracic indentations, (b) climbing ability, and (c) number of dopaminergic neurons in
parkin and PINK1 mutants fed rapamycin or vehicle (DMSO). (d-f) TEM of muscle sections
from control (DMSO) treated wild type, parkin and PINK1 mutants. (g-i) TEM of muscle
sections from rapamycin fed wild type, parkin and PINK1 mutants Scale bars show 2ͮm.
Wild types are out-crossed heterozygous mutations. Charts show mean and SEM.
Significance determined by Student’s t-test (*** P<0.001, ** P<0.01).
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Figure 5. Rapamycin rescues mitochondrial defects in parkin-deficient Drosophila and human
cells
Analysis of mitochondrial aspect ratio (length) in (a) parkin RNAi treated Drosophila cells,
and (b) fibroblasts from individuals with parkin mutations after exposure to rapamycin or
vehicle. (c) Mitochondrial membrane potential in human parkin-deficient fibroblasts after
rapamycin or control treatment. Charts show mean and SEM. Statistical analyses were
performed using Kruskal-Wallis test with Dunn’s comparison for Drosophila cells or two-
way ANOVA for fibroblast lines (*** P<0.001, ** P<0.01, * P<0.05).
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Figure 6. Rapamycin suppression of parkin/PINK1 phenotypes is dependent on 4E-BP but does
not require autophagy
Effects of rapamycin on (a,c) viability or (b,d) thoracic indentations in parkin and PINK1
mutants in combination with Thor2 mutations or RNAi-mediated knockdown of Atg5.
Charts show mean and SEM of triplicate experiments. Significance determined by Mann-
Whitney tests (*** P<0.001, ** P<0.01, * P<0.05).
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Figure 7. GstS1 levels are increased by 4E-BP activation
(a) Western blot analysis of GstS1 levels in WT (w; 24B-GAL4/+), transgenic 4E-BP
overexpression (w; 24B-GAL4/UAS-4E-BP), and wild type flies treated with rapamycin or
vehicle. (b) Quantified GstS1 protein levels are normalized to a Tubulin loading control.
Charts show mean and SEM of at least three replicates. Statistical analysis was Student’s t-
test (**P<0.01, *P<0.05).
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Figure 8. Loss of Drosophila LRRK increases the hypo-phosphorylated 4E-BP and partially
suppresses parkin and PINK1 mutant phenotypes
(a) Western blot analysis of levels of phosphorylated and non-phosphorylated 4E-BP. (b)
Quantification of relative amounts of phosphorylated and non-phosphorylated 4E-BP after
normalization for total levels of 4E-BP. The mean and SEM of three independent
experiments are represented. Analysis of (c) dopaminergic neurons, (d) flight and (e)
climbing in mutant combinations. Charts show mean and SEM. Wild type is park25/+;
LRRK e03680/+.
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